载脂蛋白B脂蛋白:数量、类型、大小与冠状动脉疾病风险
结果显示apoB-P每增加1个标准差,CAD风险升高33%(HR 1.33, 95%CI 1.30-1.36),颗粒大小或亚类经apoB-P校正后无关联,Lp(a)独立增加风险。
要点
- apoB-P总数是血脂相关动脉粥样硬化风险的最准确反映指标。
- VLDL与LDL颗粒类型经相对丰度校正后对风险区分影响小。
- Lp(a)经apoB-P校正后仍独立预测CAD风险并增加预后价值。
核心结论
- 血脂相关动脉粥样硬化风险最准确由apoB-P总数反映,主要颗粒类型或大小影响不大。
- Lp(a)颗粒计数升高增加额外风险,评估致动脉粥样硬化风险宜同时考虑apoB-P和Lp(a)浓度。
研究设计与样本
- 采用多变量校正Cox回归模型分析apoB-P、VLDL/LDL浓度、大小亚类、平均颗粒直径及免疫测定Lp(a)与 incident CAD的关联。
主要发现
- apoB-P每增加1个标准差,CAD风险升高33%(HR 1.33, 95%CI 1.30-1.36)。
- VLDL每100 nmol/L的HR为1.22(1.11-1.34),LDL每100 nmol/L的HR为1.07(1.05-1.08);考虑相对丰度(LDL 91% vs VLDL 9%)后,每1-SD的HR分别为1.09(1.05-1.14)和1.24(1.19-1.30)。
- 颗粒直径或大小亚类经apoB-P校正后与CAD无关联。
- Lp(a)经apoB-P校正后关联稳健(HR 1.18, 1.16-1.20),并增加独立预后价值(AUC 0.769 vs 0.774, P < .001)。
关键数值与推荐
- apoB-P每1-SD的CAD风险HR为1.33(95%CI 1.30-1.36)。
- VLDL每100 nmol/L的HR为1.22(95%CI 1.11-1.34),LDL每100 nmol/L的HR为1.07(95%CI 1.05-1.08)。
- 经相对丰度校正后,VLDL每1-SD的HR为1.24(95%CI 1.19-1.30),LDL每1-SD的HR为1.09(95%CI 1.05-1.14)。
- Lp(a)经apoB-P校正后的HR为1.18(95%CI 1.16-1.20),AUC比较0.769 vs 0.774,P < .001。
临床怎么用
- 临床评估血脂相关动脉粥样硬化风险时,应优先关注apoB-P总数而非颗粒类型或大小。
- 在apoB-P基础上联合检测Lp(a)浓度,可更全面评估致动脉粥样硬化风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Apolipoprotein B concentration reflects the number of atherogenic lipoproteins and is recognized as a key lipid risk marker. Whether the type or size of apoB particle (apoB-P) adds predictive value for coronary artery disease (CAD) remains unclear. METHODS: A prospective analysis of 207 368 UK Biobank participants with comprehensive lipoprotein profiling and no prior history of atherosclerotic disease, diabetes, or active lipid-lowering therapy was conducted. Multivariable-adjusted Cox regression models were used to examine the association between each of the following lipid parameters with incident CAD: (i) nuclear magnetic resonance-measured apoB-P, (ii) concentrations of individual lipoprotein classes [very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL)], (iii) size subclasses, (iv) average particle diameter, and (v) immunoassay-measured lipoprotein(a) [Lp(a)]. RESULTS: A one standard deviation (SD) increase in apoB-P was associated with a 33% higher CAD risk [hazard ratio (HR): 1.33, 95% CI: 1.30-1.36]. Although VLDL particles were observed to carry a higher per-particle risk (HR per 100 nmol/L: 1.22, 1.11-1.34) compared with LDL (HR per 100 nmol/L: 1.07, 1.05-1.08), this difference was counterbalanced after considering relative particle abundance (LDL 91% vs VLDL 9% of total apoB-P). Thus the respective HR per 1-SD were 1.09 (1.05-1.14) and 1.24 (1.19-1.30). Particle diameter or size subclasses were not associated with CAD after apoB-P adjustment. The association of Lp(a) was robust even after apoB-P adjustment (HR:1.18, 1.16-1.20) and added independent prognostic value for CAD (area under curve: 0.769 vs 0.774, P < .001). CONCLUSIONS: Lipid-related atherosclerotic risk is most accurately reflected by the total count of apoB-P and is largely unaffected by the major particle type (VLDL, LDL) or size. Elevated count of Lp(a) adds additional risk, and thus adequate assessment of atherogenic risk from dyslipidemia is best accomplished by consideration of both apoB-P and Lp(a) concentrations.
引用
- Morze J, Melloni GEM, Wittenbecher C, et al. ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease. Eur Heart J. 2025. PMID: 40289348. doi:10.1093/eurheartj/ehaf207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。